samedan logo
 
 
 
spacer
home > ebr > spring 2003 > assessing the safety of inhaled biopharmaceuticals - current issues and recent developments
PUBLICATIONS
European Biopharmaceutical Review

Assessing the Safety of Inhaled Biopharmaceuticals - Current Issues and Recent Developments

It has long been recognised that inhalation is a very efficient means of introducing foreign substances into the body. As long as 500 years ago, Leonardo da Vinci realised that inhaled dust could cause lung pathology and so annotated one of his anatomical drawings of lungs - in his characteristic mirror writing - "polvere fa danno" or "dust causes damage".

The importance of inhalation as a route of exposure to injurious substances has long been recognised. For example ...


Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
By Dr Colin J Hardy, Director of Inhalation Studies at Huntingdon Life Sciences

Dr Colin J Hardy has over 30 years' experience in the safety assessment of inhaled pharmaceutical products. His first degree was in Biological Sciences, specialising in respiratory physiology, and his Doctorate was awarded for work on the effects of inhaled fibres.

Dr Hardy subsequently specialised in lung function testing in laboratory animals before moving into the wider field of inhalation safety assessment. He is currently Director of Inhalation Studies at Huntingdon Life Sciences.

spacer
Dr Colin J Hardy
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Business Continuity Plan - Message from Protagen Protein Services (PPS)

Following the recent COVID-19 outbreak, we at Protagen Protein Services (PPS) are preparing for all eventualities. Please be assured that PPS will continue to operate as normal providing you with all of the professional support and service you have to come to expect from us. Given the gravity of the situation, and to protect our staff, clients, and communities from the spread of the virus, we have taken various measures within a scope of a Business Continuity Plan:
More info >>

White Papers

The Flexible Factory Concept: A flexible bioprocessing platform to meet the changing needs of biomanufacturing

GE Healthcare Life Sciences

For the past several years, the biopharma industry has been buffeted by dynamic market conditions that are rapidly reshaping manufacturing requirements. These factors include: • The rise of small-market pharmaceuticals that do not require the production scale of the previous “blockbuster” drug model • Increased titers and process productivity that generate more bulk-product within a much smaller manufacturing footprint • The emergence of biosimilars and continued evolution of healthcare reform, which will increasingly pressure drug pricing and require greater cost discipline • Greater competition and shorter patent protection timelines, which will further ratchet up time-to-market pressures • Tighter capital markets that will create heightened scrutiny for all new investment projects
More info >>

 
Industry Events

World Vaccine Congress Washington

27-29 September 2020, Walter E Washington Convention Center, Washington, US

The World Vaccine Congress is an award-winning series of conferences and exhibitions that have grown to become the largest and most established vaccine meeting of its kind across the globe. Our credibility is show through the prestigious scientific advisory board that spend months of hard work creating a new and topical agenda, year on year.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement